CELLEBRATE: An Adaptive, Two-Stage, Double-Blind, Stratified, Randomized, Controlled Trial Comparing the Safety and Efficacy of AMDC-USR With Placebo in Female Subjects With Stress Urinary Incontinence
Phase of Trial: Phase III
Latest Information Update: 22 Nov 2019
Price : $35 *
At a glance
- Drugs Autologous muscle-derived stem cell therapy Cook MyoSite (Primary)
- Indications Stress incontinence
- Focus Registrational; Therapeutic Use
- Acronyms CELLEBRATE
- Sponsors Cook MyoSite
- 18 Jan 2019 Status changed from not yet recruiting to recruiting.
- 31 Jul 2018 Planned End Date changed from 1 Aug 2023 to 1 Sep 2023.
- 31 Jul 2018 Planned primary completion date changed from 1 Jul 2022 to 1 Sep 2022.